Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors

dc.contributor.author	Juchum, Michael
dc.contributor.author	Pfaffenrot, Bent
dc.contributor.author	Klovekorn, Philip
dc.contributor.author	Zender, Lars
dc.contributor.author	Selig, Roland
dc.contributor.author	Laufer, Stefan
dc.date.accessioned	2023-11-21T07:55:11Z
dc.date.available	2023-11-21T07:55:11Z
dc.date.issued	2022
dc.identifier.issn	0223-5234
dc.identifier.uri	http://hdl.handle.net/10900/147925
dc.language.iso	en	de_DE
dc.publisher	Elsevier France - Editions Scientifiques Medicales Elsevier	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.ejmech.2022.114584	de_DE
dc.subject.ddc	540	de_DE
dc.title	Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors	de_DE
dc.type	Article	de_DE
utue.quellen.id	20230202000000_02208
utue.personen.roh	Juchum, Michael
utue.personen.roh	Pfaffenrot, Bent
utue.personen.roh	Klovekorn, Philip
utue.personen.roh	Selig, Roland
utue.personen.roh	Albrecht, Wolfgang
utue.personen.roh	Zender, Lars
utue.personen.roh	Laufer, Stefan A.
dcterms.isPartOf.ZSTitelID	European Journal of Medicinal Chemistry	de_DE
dcterms.isPartOf.ZS-Issue	Article 114584	de_DE
dcterms.isPartOf.ZS-Volume	240	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE
utue.fakultaet	07 Mathematisch-Naturwissenschaftliche Fakultät	de_DE